Index RUT
P/E -
EPS (ttm) -0.73
Insider Own 30.68%
Shs Outstand 62.31M
Perf Week 17.69%
Market Cap 95.33M
Forward P/E -
EPS next Y -0.92
Insider Trans -0.28%
Shs Float 43.19M
Perf Month 22.40%
Income -41.61M
PEG -
EPS next Q -0.16
Inst Own 16.19%
Short Float 18.47%
Perf Quarter -47.24%
Sales 0.00M
P/S -
EPS this Y 1.35%
Inst Trans 2.04%
Short Ratio 10.62
Perf Half Y -30.14%
Book/sh -1.52
P/B -
EPS next Y -26.03%
ROA -176.31%
Short Interest 7.98M
Perf Year -11.56%
Cash/sh 0.43
P/C 3.52
EPS next 5Y -15.49%
ROE -
52W Range 0.73 - 4.27
Perf YTD 18.60%
Dividend Est. -
P/FCF -
EPS past 5Y -14.30%
ROI -2675.95%
52W High -64.16%
Beta 0.74
Dividend TTM -
Quick Ratio 1.13
Sales past 5Y 0.00%
Gross Margin -
52W Low 110.73%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 1.13
EPS Y/Y TTM 4.53%
Oper. Margin -
RSI (14) 65.97
Volatility 8.46% 6.41%
Employees 14
Debt/Eq -
Sales Y/Y TTM -
Profit Margin -
Recom 3.00
Target Price 11.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 23.30%
Payout -
Rel Volume 0.95
Prev Close 1.41
Sales Surprise -
EPS Surprise 10.00%
Sales Q/Q -
Earnings Nov 14 BMO
Avg Volume 750.94K
Price 1.53
SMA20 19.34%
SMA50 8.29%
SMA200 -34.20%
Trades
Volume 716,629
Change 8.51%
Date
Action
Analyst
Rating Change
Price Target Change
Aug-13-20 Reiterated
H.C. Wainwright
Buy
$9 → $12
Feb-13-19 Initiated
B. Riley FBR
Buy
$11
Dec-07-17 Reiterated
H.C. Wainwright
Buy
$6 → $10
Nov-28-17 Reiterated
H.C. Wainwright
Buy
$3.50 → $6
Oct-19-17 Initiated
ROTH Capital
Buy
Mar-30-17 Upgrade
H.C. Wainwright
Neutral → Buy
$3.50
Oct-03-16 Downgrade
FBR & Co.
Outperform → Mkt Perform
$12 → $2
Sep-29-16 Downgrade
H.C. Wainwright
Buy → Neutral
$1.50
Sep-28-16 Downgrade
ROTH Capital
Buy → Sell
Mar-28-16 Resumed
H.C. Wainwright
Buy
$8
Sep-21-15 Initiated
H.C. Wainwright
Buy
$7
Aug-01-14 Downgrade
Aegis Capital
Buy → Hold
Jul-30-14 Reiterated
MLV & Co
Buy
$27 → $16
Jul-29-14 Reiterated
MLV & Co
Buy
$27 → $15
Apr-02-14 Reiterated
MLV & Co
Buy
$20 → $27
Feb-10-14 Reiterated
Aegis Capital
Buy
$16 → $32
Jan-09-14 Reiterated
Aegis Capital
Buy
$10 → $16
Dec-03-13 Initiated
MLV & Co
Buy
$20
Aug-19-13 Reiterated
Aegis Capital
Buy
$7 → $10
Show Previous Ratings
Today 08:00AM
Jan-10-25 08:00AM
Dec-20-24 08:00AM
Dec-09-24 09:35AM
Nov-18-24 08:00AM
08:00AM
Loading…
Nov-14-24 08:00AM
Oct-15-24 08:00AM
Sep-30-24 08:00AM
Sep-03-24 08:30AM
Aug-13-24 08:00AM
Aug-01-24 08:00AM
Jun-04-24 08:00AM
May-15-24 12:53PM
08:00AM
May-13-24 08:00AM
08:00AM
Loading…
Apr-09-24 08:00AM
Apr-05-24 08:52AM
Mar-29-24 09:11AM
08:00AM
Mar-12-24 08:00AM
Nov-13-23 11:11AM
08:45AM
08:00AM
Nov-03-23 08:00AM
Oct-23-23 08:00AM
Oct-12-23 08:00AM
Oct-03-23 08:00AM
Sep-26-23 08:00AM
Sep-13-23 05:22PM
Sep-11-23 09:55AM
08:00AM
Loading…
08:00AM
Sep-07-23 12:00PM
Aug-17-23 12:00PM
Aug-14-23 08:00AM
May-18-23 04:37PM
May-15-23 08:00AM
Apr-27-23 08:00AM
Apr-18-23 08:00AM
Mar-30-23 08:00AM
Mar-16-23 08:00AM
Mar-02-23 08:00AM
Jan-24-23 08:00AM
Jan-05-23 08:00AM
Dec-13-22 09:55AM
Nov-29-22 08:00AM
Nov-28-22 08:00AM
Nov-14-22 08:00AM
Nov-01-22 08:00AM
Oct-14-22 08:00AM
Oct-12-22 08:00AM
Oct-06-22 08:00AM
Sep-08-22 08:00AM
Aug-15-22 08:00AM
Jul-26-22 08:00AM
Jun-21-22 08:00AM
May-23-22 08:00AM
May-16-22 08:00AM
May-11-22 11:20AM
May-03-22 08:30AM
Apr-15-22 07:20AM
Apr-14-22 08:00AM
Mar-31-22 08:00AM
Jan-06-22 08:00AM
Dec-21-21 08:00AM
Dec-13-21 08:00AM
Nov-15-21 08:00AM
Nov-05-21 04:24PM
Oct-27-21 08:00AM
Oct-05-21 03:39PM
01:55PM
Sep-21-21 08:00AM
Sep-09-21 09:00AM
Aug-30-21 08:00AM
Aug-16-21 09:00AM
Jul-30-21 04:28AM
Jul-09-21 09:25AM
08:00AM
06:29AM
Jun-13-21 11:23PM
May-17-21 08:00AM
Apr-27-21 09:28AM
Apr-19-21 08:00AM
Apr-15-21 09:00AM
Apr-14-21 08:28AM
Apr-13-21 07:01PM
Apr-06-21 08:00AM
Mar-31-21 08:00AM
Mar-08-21 08:00AM
Mar-04-21 08:00AM
Jan-31-21 02:28AM
Jan-19-21 11:15AM
Dec-11-20 08:00AM
Dec-04-20 04:17PM
Dec-01-20 08:00AM
Nov-09-20 08:00AM
Nov-02-20 08:02AM
Oct-12-20 08:11AM
Oct-06-20 03:30PM
Sep-29-20 12:00PM
08:52AM
Galectin Therapeutics, Inc. is a biotechnology company, which engages in drug research and development to create new therapies for fibrotic disease, severe skin disease, and cancer. Its programs target the development of carbohydrate molecules which offers alternative options to larger market segments. The company was founded by James C. Czirr and Anatole A. Klyosov on July 10, 2000 and is headquartered in Norcross, GA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Shlevin Harold H. Director Dec 30 '24 Buy 1.16 6,500 7,540 15,206 Dec 31 07:45 AM Jamil Khurram Chief Medical Officer Dec 23 '24 Option Exercise 0.00 40,000 0 40,000 Dec 26 08:20 AM Jamil Khurram Chief Medical Officer Dec 23 '24 Sale 0.88 13,654 12,044 26,346 Dec 26 08:20 AM LEWIS JOEL President and CEO Dec 23 '24 Option Exercise 0.00 56,000 0 953,012 Dec 26 08:18 AM LEWIS JOEL President and CEO Dec 23 '24 Sale 0.89 56,000 49,610 897,012 Dec 26 08:18 AM CALLICUTT JACK W Chief Financial Officer Dec 23 '24 Option Exercise 0.00 40,000 0 47,614 Dec 26 08:18 AM CALLICUTT JACK W Chief Financial Officer Dec 23 '24 Sale 0.89 40,000 35,492 7,614 Dec 26 08:18 AM Zordani Richard A. Jr. Director Dec 24 '24 Buy 0.82 10,000 8,164 42,083 Dec 26 08:16 AM ELDRED KARY Director Dec 24 '24 Buy 0.82 13,469 11,045 63,682 Dec 26 08:07 AM FREEMAN KEVIN D Director Dec 24 '24 Buy 0.81 10,000 8,134 44,769 Dec 26 08:02 AM Jamil Khurram Officer Dec 23 '24 Proposed Sale 1.04 13,654 14,200 Dec 23 04:19 PM LEWIS JOEL Officer Dec 23 '24 Proposed Sale 1.04 56,000 58,240 Dec 23 04:18 PM CALLICUTT JACK W Officer Dec 23 '24 Proposed Sale 1.04 40,000 41,600 Dec 23 04:17 PM ELDRED KARY Director Oct 23 '24 Buy 2.60 500 1,300 50,213 Oct 23 01:39 PM FREEMAN KEVIN D Director Oct 17 '24 Buy 2.64 1,300 3,432 34,769 Oct 17 04:03 PM FREEMAN KEVIN D Director Oct 16 '24 Buy 2.70 5,000 13,500 80,000 Oct 16 04:12 PM FREEMAN KEVIN D Director Oct 16 '24 Buy 2.70 5,000 13,500 33,469 Oct 16 04:12 PM Boudes Pol F Officer Oct 04 '24 Proposed Sale 2.70 453,750 1,225,044 Oct 04 04:10 PM Zordani Richard A. Jr. Director Aug 23 '24 Buy 2.30 1,759 4,046 32,083 Aug 26 08:08 AM Zordani Richard A. Jr. Director Aug 23 '24 Buy 2.30 1,000 2,300 2,000 Aug 26 08:08 AM Zordani Richard A. Jr. Director Aug 22 '24 Buy 2.30 741 1,704 30,324 Aug 26 08:08 AM FREEMAN KEVIN D Director Jun 20 '24 Buy 2.38 2,500 5,950 28,469 Jun 20 01:55 PM Zordani Richard A. Jr. Director Apr 30 '24 Buy 3.52 1,000 3,520 1,000 Apr 30 02:14 PM LEWIS JOEL President and CEO Apr 24 '24 Buy 3.39 1,000 3,390 2,000 Apr 25 01:27 PM CZIRR JAMES C 10% Owner Apr 22 '24 Sale 3.06 21,323 65,248 5,925,884 Apr 25 11:36 AM CZIRR JAMES C 10% Owner Apr 23 '24 Sale 3.06 3,677 11,252 5,922,207 Apr 25 11:36 AM FREEMAN KEVIN D Director Apr 22 '24 Buy 2.98 2,500 7,450 25,969 Apr 22 04:04 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite